<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE HTML>
<html xml:lang="en" xmlns="http://www.w3.org/1999/xhtml" lang="en">
  <head>
    <meta http-equiv="Content-Type" content="text/html;charset=utf-8"/>
    <title>DE.UNI-GREIFSWALD.MEDIZIN.CLL-GUIDELINE\Table of Contents - FHIR v5.0.0</title>

    <meta name="viewport" content="width=device-width, initial-scale=1.0"/>
    <meta name="author" content="http://hl7.org/fhir"/>

    <link rel="stylesheet" href="fhir.css"/>

      <!-- Bootstrap core CSS -->
    <link rel="stylesheet" href="assets/css/bootstrap-fhir.css"/>

      <!-- Project extras -->
    <link rel="stylesheet" href="assets/css/project.css"/>
    <link rel="stylesheet" href="assets/css/pygments-manni.css"/>
    <link rel="stylesheet" href="assets/css/jquery-ui.css"/>
  	<link rel="stylesheet" href="assets/css/prism.css"/>
      <!-- Placeholder for child template CSS declarations -->
  <!-- Placeholder for child template CSS declarations -->
<link rel="stylesheet" href="assets/css/colors.css"/>
<link rel="stylesheet" href="assets/css/celida.css"/>


    <script src="assets/js/fhir-table-scripts.js" type="text/javascript"> </script>

      <!-- HTML5 shim and Respond.js IE8 support of HTML5 elements and media queries -->
      <!-- [if lt IE 9]>
    <script src="assets/js/html5shiv.js"></script>
    <script src="assets/js/respond.min.js"></script>
    <![endif] -->

      <!-- Favicons -->
    <link sizes="144x144" rel="apple-touch-icon-precomposed" href="assets/ico/apple-touch-icon-144-precomposed.png"/>
    <link sizes="114x114" rel="apple-touch-icon-precomposed" href="assets/ico/apple-touch-icon-114-precomposed.png"/>
    <link sizes="72x72" rel="apple-touch-icon-precomposed" href="assets/ico/apple-touch-icon-72-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" href="assets/ico/apple-touch-icon-57-precomposed.png"/>
    <link rel="shortcut icon" href="assets/ico/favicon.png"/>
  </head>
  <body onload="document.body.style.opacity='1'">

	  <script src="assets/js/prism.js"></script>

    <style type="text/css">h2{--heading-prefix:"0"}
    h3,h4,h5,h6{--heading-prefix:"0.0"}</style>
    <div id="segment-header" class="segment">    <!-- segment-header -->
      <div class="container">    <!-- container -->
          <!-- Left logo - typically the publisher's logo - project or affiliate -->
<div id="project-nav">
  <a no-external="true" id="project-logo" href="https://www.github.com/CODEX-CELIDA/">
    <img src="assets/images/logo_celida.png" alt="Project home" height="71"/>
  </a>
</div>

  <!-- Right logo - for example the FHIR logo -->
  <!-- Make sure you have authorization to use the FHIR logo -->
<div id="family-nav">
  <a no-external="true" id="family-logo" href="https://www.netzwerk-universitaetsmedizin.de">
    <img src="assets/images/logo_num.svg" alt="FHIR website" height="70"/>
  </a>
</div>


        <div id="ig-status">
          <p><span style="font-size:12pt;font-weight:bold">Chronisch Lymphatische Leukämie Guidline and Quality indicator</span><br/>0.2.0 - ci-build</p>
        </div>
      </div>   <!-- /container -->
    </div>    <!-- /segment-header -->

    <div id="segment-navbar" class="segment">    <!-- segment-navbar -->
      <div id="stripe"> </div>
      <div class="container">    <!-- container -->
          <!-- HEADER CONTENT -->

        <nav class="navbar navbar-inverse">
            <!-- status-bar -->
          <div class="container">
            <button data-target=".navbar-inverse-collapse" data-toggle="collapse" type="button" class="navbar-toggle">
              <span class="icon-bar"> </span>
              <span class="icon-bar"> </span>
              <span class="icon-bar"> </span>
            </button>
            <a href="http://hl7.org/fhir/R5/index.html" class="navbar-brand hidden">FHIR</a>
            <div class="nav-collapse collapse navbar-inverse-collapse">
                <!-- menu.xml -->

<ul class="nav navbar-nav">
  <li>
    <a href="index.html">Home</a>
  </li>
  <li>
    <a href="artifacts.html">Artifacts</a>
  </li>
  <li>
    <a href="downloads.html">Downloads</a>
  </li>
  <li>
    <a href="changelog.html">Change Log</a>
  </li>
</ul>
            </div>    <!-- /.nav-collapse -->
          </div>    <!-- /.container -->
        </nav>    <!-- /.navbar -->
        <!-- /HEADER CONTENT -->
      </div>    <!-- /container -->
    </div>    <!-- /segment-navbar -->
      <!-- status-bar -->

    <div id="segment-breadcrumb" class="segment">    <!-- segment-breadcrumb -->
      <div class="container">    <!-- container -->
        <ul class="breadcrumb">
          <li><b>Table of Contents</b></li>

        </ul>
      </div>    <!-- /container -->
    </div>    <!-- /segment-breadcrumb -->

    <a name="top"> </a>
    <div id="segment-content" class="segment">    <!-- segment-content -->
      <div class="container">    <!-- container -->
        <div class="row">
          <div class="inner-wrapper">

<style type="text/css">
h2:before{color:silver;counter-increment:section;content:var(--heading-prefix) " ";}
h3:before{color:silver;counter-increment:sub-section;content:var(--heading-prefix) "." counter(sub-section) " ";}
h4:before{color:silver;counter-increment:composite;content:var(--heading-prefix) "." counter(sub-section) "." counter(composite) " ";}
h5:before{color:silver;counter-increment:detail;content:var(--heading-prefix) "." counter(sub-section) "." counter(composite) "." counter(detail) " ";}
h6:before{color:silver;counter-increment:more-detail;content:var(--heading-prefix) "." counter(sub-section) "." counter(composite) "." counter(detail) "." counter(more-detail)" ";}
</style>
<div class="col-12">
    <!-- ReleaseHeader --><p id="publish-box">Chronisch Lymphatische Leukämie Guidline and Quality indicator - Local Development build (v0.2.0) built by the FHIR (HL7&reg; FHIR&reg; Standard) Build Tools. See the <a href="https://www.medizin.uni-greifswald.de/fhir/guideline/cll/history.html">Directory of published versions</a></p>  <!-- EndReleaseHeader -->
  <h2>Table of Contents</h2>
  
  
  
    <!-- ?xml version="1.0" encoding="UTF-8"? --><div style="col-12"><table border="0" cellpadding="0" cellspacing="0" style="border:0px;font-size:11px;font-family:verdana;vertical-align:top;"><tbody><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page-child.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="toc.html" title="Table of Contents"> 0 Table of Contents</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!&quot;"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="index.html" title="Index"> 1 Index</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!#"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="downloads.html" title="Downloads"> 2 Downloads</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!$"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="changelog.html" title="Change Log"> 3 Change Log</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img onClick="tableRowAction(this)" src="tbl_vjoin_end-open.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="icon_page-child.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="artifacts.html" title="Artifacts Summary"> 4 Artifacts Summary</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%&quot;"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="ActivityDefinition-AbdomialUltrasonographyCLL.html" title="Abdomial Ultrasonography CLL"> 4.1 Abdomial Ultrasonography CLL</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%#"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="ActivityDefinition-AssessmentComorbiditiesCLL.html" title="Assesment Comorbidities CLL"> 4.2 Assesment Comorbidities CLL</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%$"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="ActivityDefinition-AssessmentECOGScoreCLL.html" title="Assesment ECOG Score CLL"> 4.3 Assesment ECOG Score CLL</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%%"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="ActivityDefinition-AssessmentKarnofskyIndexCLL.html" title="Assesment Karnofsky-Index CLL"> 4.4 Assesment Karnofsky-Index CLL</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%&amp;"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="ActivityDefinition-BinetStagingCLL.html" title="Binet Staging CLL"> 4.5 Binet Staging CLL</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%'"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="ActivityDefinition-ClinicalChemistryTestCLL.html" title="Clinical Chemistry Test CLL"> 4.6 Clinical Chemistry Test CLL</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%("><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="ActivityDefinition-CLLPatientInCLLRelapseStudy.html" title="CLLPatientInCLLRelapseStudy"> 4.7 CLLPatientInCLLRelapseStudy</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%)"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="ActivityDefinition-CMVAntibodyIgGCLL.html" title="CMV IgG Antibody CLL"> 4.8 CMV IgG Antibody CLL</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%*"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="ActivityDefinition-CMVAntibodyIgMCLL.html" title="CMV IgM Antibody CLL"> 4.9 CMV IgM Antibody CLL</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%+"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="ActivityDefinition-CMVPCRCLL.html" title="CMV PCR CLL"> 4.10 CMV PCR CLL</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%,"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="ActivityDefinition-CompleteBloodCountAutomatedCLL.html" title="Complete Blood Count and White cell Differential Automated CLL"> 4.11 Complete Blood Count and White cell Differential Automated CLL</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%-"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="ActivityDefinition-ErstlinieMitBCL2beiCLL.html" title="Erstlinienterapie mit BCL2-Inhibitor bei CLL"> 4.12 Erstlinienterapie mit BCL2-Inhibitor bei CLL</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%."><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="ActivityDefinition-RezidivtherapieMitBCL2beiCLL.html" title="Erstlinienterapie mit BCL2-Inhibitor bei CLL"> 4.13 Erstlinienterapie mit BCL2-Inhibitor bei CLL</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%/"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="ActivityDefinition-ExaminationLiverSizeCLL.html" title="Examination liver size CLL"> 4.14 Examination liver size CLL</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%0"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="ActivityDefinition-ExaminationLymphaticNodesCLL.html" title="Examination Lymphatic nodes CLL"> 4.15 Examination Lymphatic nodes CLL</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%1"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="ActivityDefinition-ExaminationSpleenSizeCLL.html" title="Examination spleen size CLL"> 4.16 Examination spleen size CLL</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%2"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="ActivityDefinition-TP53andDEL17pCLL.html" title="FISH hinsichtlich TP53 und DEL17p"> 4.17 FISH hinsichtlich TP53 und DEL17p</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%3"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="ActivityDefinition-HBVSerologyCLL.html" title="HBV Serology CLL"> 4.18 HBV Serology CLL</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%4"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="ActivityDefinition-HCVSerologyCLL.html" title="HCV Serology CLL"> 4.19 HCV Serology CLL</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%5"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="ActivityDefinition-HEVSerologyCLL.html" title="HEV Serology CLL"> 4.20 HEV Serology CLL</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%6"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="ActivityDefinition-HistoryTakingCLL.html" title="History Taking CLL"> 4.21 History Taking CLL</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%7"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="ActivityDefinition-HIVSerologyCLL.html" title="HIV Serology CLL"> 4.22 HIV Serology CLL</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%8"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="ActivityDefinition-IGHVmutationCLL.html" title="IGHV-Mutationsstatus"> 4.23 IGHV-Mutationsstatus</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%9"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="ActivityDefinition-PhysicalExaminationCLL.html" title="Physical Examination CLL"> 4.24 Physical Examination CLL</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%:"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="ActivityDefinition-PregnancyTestbHCGCLL.html" title="Pregnancy Test betaHCG CLL"> 4.25 Pregnancy Test betaHCG CLL</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%;"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="ActivityDefinition-ErstlinieMitBTKbeiCLL.html" title="Rezidivtherapie mit BTK-Inhibitor bei CLL"> 4.26 Rezidivtherapie mit BTK-Inhibitor bei CLL</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%&lt;"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="ActivityDefinition-RezidivtherapieMitBTKbeiCLL.html" title="Rezidivtherapie mit BTK-Inhibitor bei CLL"> 4.27 Rezidivtherapie mit BTK-Inhibitor bei CLL</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%="><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="ActivityDefinition-TherapieIndikationCLL.html" title="TherapieIndikationCLL"> 4.28 TherapieIndikationCLL</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%&gt;"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="ActivityDefinition-MicroscopyWhiteBloodCellCountCLL.html" title="White cell Differential Microscopy CLL"> 4.29 White cell Differential Microscopy CLL</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%?"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="PlanDefinition-CLLTherapieindikationBinetAB.html" title="CLL Therapieindikation Binet A B"> 4.30 CLL Therapieindikation Binet A B</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%@"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="PlanDefinition-CLLTherapieindikationBinetC.html" title="CLL Therapieindikation Binet C"> 4.31 CLL Therapieindikation Binet C</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%A"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="PlanDefinition-ErstlinieBCL2undBTKbeiCLL.html" title="Erstlinientherapie mit BCL-2- und oder BTK-Inhibitor bei CLL"> 4.32 Erstlinientherapie mit BCL-2- und oder BTK-Inhibitor bei CLL</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%B"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="PlanDefinition-QIMutationsstatusVorTherapie.html" title="QI 2: Bestimmung TP53-Deletions- und TP53-/IGHV-Mutationsstatus vor erster systemischer CLL-Therapie (modifiziert 2024)"> 4.33 QI 2: Bestimmung TP53-Deletions- und TP53-/IGHV-Mutationsstatus vor erster systemischer CLL-Therapie (modifiziert 2024)</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%C"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="PlanDefinition-RecCollectionQIMutationsstatusVorTherapie.html" title="QI 2: Bestimmung TP53-Deletions- und TP53-/IGHV-Mutationsstatus vor erster systemischer CLL-Therapie (modifiziert 2024)"> 4.34 QI 2: Bestimmung TP53-Deletions- und TP53-/IGHV-Mutationsstatus vor erster systemischer CLL-Therapie (modifiziert 2024)</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%D"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="PlanDefinition-RecCollectionQIRezidivKlinischeStudien.html" title="QI 4: Einschluss von CLL-Pat. mit Rezidiv in klinische Studien (modifiziert 2024)"> 4.35 QI 4: Einschluss von CLL-Pat. mit Rezidiv in klinische Studien (modifiziert 2024)</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%E"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="PlanDefinition-QIRezidivKlinischeStudien.html" title="QI 4: Einschluss von CLL-Pat. mit Rezidiv in klinische Studien (modifiziert 2024))"> 4.36 QI 4: Einschluss von CLL-Pat. mit Rezidiv in klinische Studien (modifiziert 2024))</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%F"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="PlanDefinition-QICLLErstlinienTherapie.html" title="QI 5: Bcl-2- oder BTK-Inhibitor-basierten Therapie als Erstlinientherapie (neu 2024)"> 4.37 QI 5: Bcl-2- oder BTK-Inhibitor-basierten Therapie als Erstlinientherapie (neu 2024)</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%G"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="PlanDefinition-RecCollectionQIMedikationErstlinienTherapie.html" title="QI 5: Bcl-2- oder BTK-Inhibitor-basierten Therapie als Erstlinientherapie (neu 2024)"> 4.38 QI 5: Bcl-2- oder BTK-Inhibitor-basierten Therapie als Erstlinientherapie (neu 2024)</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%H"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="PlanDefinition-RecCollectionErstlinieBCL2undBTKbeiCLL.html" title="Recommendation Collection CLL: Erstlinien-Behandlung mit BCL-2-Inhib. Oder BTK-Inhibitor (4.3)"> 4.39 Recommendation Collection CLL: Erstlinien-Behandlung mit BCL-2-Inhib. Oder BTK-Inhibitor (4.3)</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%I"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="PlanDefinition-RecCollectionRezidivtherapieBCL2undBTKbeiCLL.html" title="Recommendation Collection CLL: Rezidivbehandlung mit BCL-2-Inhib. Oder BTK-Inhibitor (5.4)"> 4.40 Recommendation Collection CLL: Rezidivbehandlung mit BCL-2-Inhib. Oder BTK-Inhibitor (5.4)</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%J"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="PlanDefinition-RecCollectionTherapieplanungBinetCLL.html" title="Recommendation Collection CLL: Therapieindikation nach Binet Stadium (4.1)"> 4.41 Recommendation Collection CLL: Therapieindikation nach Binet Stadium (4.1)</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%K"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="PlanDefinition-RecCollectionUntersuchungenVorCLLPlanungOnkoTherapie.html" title="Recommendation Collection CLL: Untersuchungen vor Therapieeinleitung (3.11)"> 4.42 Recommendation Collection CLL: Untersuchungen vor Therapieeinleitung (3.11)</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%L"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="PlanDefinition-RezidivBehandlungBCL2undBTKbeiCLL.html" title="Rezidivbehandlung mit BCL-2-Inhib. Oder Acalabrutinib"> 4.43 Rezidivbehandlung mit BCL-2-Inhib. Oder Acalabrutinib</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%M"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="PlanDefinition-UntersuchungenVorCLLPlanungOnkoTherapie.html" title="Untersuchung vor Einleitung einer CLL Therapielinie "> 4.44 Untersuchung vor Einleitung einer CLL Therapielinie </a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%N"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="PlanDefinition-UntersuchungenVorPlanungOnkoTherapieFertileFemale.html" title="Untersuchung vor Einleitung einer CLL Therapielinie bei gebährfähige Frauen"> 4.45 Untersuchung vor Einleitung einer CLL Therapielinie bei gebährfähige Frauen</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%O"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="PlanDefinition-UntersuchungenVorPlanungOnkoTherapieIdelalisib.html" title="Untersuchung vor Einleitung einer CLL Therapielinie mit Idelalisib"> 4.46 Untersuchung vor Einleitung einer CLL Therapielinie mit Idelalisib</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%P"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="PlanDefinition-UntersuchungenWhileTherapieIdelalisib.html" title="Untersuchung waehrend CLL Therapielinie mit Idelalisib"> 4.47 Untersuchung waehrend CLL Therapielinie mit Idelalisib</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%Q"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="CodeSystem-cll-v2.html" title="CLL_V2"> 4.48 CLL_V2</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%R"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="EvidenceVariable-PopulationQIRezidivKlinischeStudien.html" title="Population CLL Rezidiv einschluss in klinische Studien"> 4.49 Population CLL Rezidiv einschluss in klinische Studien</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%S"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="EvidenceVariable-PopulationQIMedikationErstlinienTherapie.html" title="Population für CLL Erstlinien-Therapie"> 4.50 Population für CLL Erstlinien-Therapie</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%T"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="EvidenceVariable-PopulationQIMutationsstatusVorTherapie.html" title="Population Genetischer Mutationsstatus vor Therapie"> 4.51 Population Genetischer Mutationsstatus vor Therapie</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%U"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="EvidenceVariable-PopulationCLLOnkoTherapieIdelalisib.html" title="Population: CLL onkologische Therapielinie mit Idelalisib Frauen"> 4.52 Population: CLL onkologische Therapielinie mit Idelalisib Frauen</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%V"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="EvidenceVariable-PopulationCLLBinetAB.html" title="Population: CLL und Binet Stadium AB "> 4.53 Population: CLL und Binet Stadium AB </a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%W"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="EvidenceVariable-PopulationCLLBinetC.html" title="Population: CLL und Binet Stadium C"> 4.54 Population: CLL und Binet Stadium C</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%X"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="EvidenceVariable-PopulationCLLErstlinientherapie.html" title="Population: CLL und Erstlinientherapie"> 4.55 Population: CLL und Erstlinientherapie</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%Y"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="EvidenceVariable-PopulationCLLPlanungOnkoTherapie.html" title="Population: CLL und Planung Onkologische Therapielinie"> 4.56 Population: CLL und Planung Onkologische Therapielinie</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%Z"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="EvidenceVariable-PopulationCLLPlanungOnkoTherapieFertileFemale.html" title="Population: CLL und Planung Onkologische Therapielinie gebährfähige Frauen"> 4.57 Population: CLL und Planung Onkologische Therapielinie gebährfähige Frauen</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%["><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="EvidenceVariable-PopulationCLLPlanungOnkoTherapieIdelalisib.html" title="Population: CLL und Planung Onkologische Therapielinie mit Idelalisib"> 4.58 Population: CLL und Planung Onkologische Therapielinie mit Idelalisib</a></td></tr><tr style="border:0px;padding:0px;vertical-align:top;background-color:inherit;" id="!%\"><td style="vertical-align:top;text-align:left;background-color:inherit;padding:0px 4px 0px 4px;white-space:nowrap;background-image:url(tbl_bck0.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="tbl_vjoin_end.png" alt="." style="background-color:inherit" class="hierarchy"/><img src="icon_page.gif" alt="." style="background-color:inherit" class="hierarchy"/><a href="EvidenceVariable-PopulationCLLRezidivtherapie.html" title="Population: CLL und Rezidivtherapie"> 4.59 Population: CLL und Rezidivtherapie</a></td></tr></tbody></table></div>
</div>
        </div>    <!-- /inner-wrapper -->
      </div>    <!-- /row -->
    </div>    <!-- /container -->
  </div>    <!-- /segment-content -->

  <script src="assets/js/jquery.js" type="text/javascript"> </script>       <!-- note keep space here, otherwise it will be transformed to empty tag -> fails -->
  <script src="assets/js/jquery-ui.min.js" type="text/javascript"> </script>

  <script type="text/javascript">
    $(document).ready(function(){
      if(window.location.hash != "") {
          $('a[href="' + window.location.hash + '"]').click()
      }
    });
  </script>
  <div igtool="footer" id="segment-footer" class="segment">    <!-- segment-footer -->
    <div class="container">    <!-- container -->
      <div class="inner-wrapper">
        <p>
          IG &copy; 2023+ <a href="https://www.medizin.uni-greifswald.de/intensiv/">Universitätsmedizin Greifswald, Klink für Anästhesie, Intensiv-, Notfall- und Schmerzmedizin</a>.  Package de.uni-greifswald.medizin.cll-guideline#0.2.0 based on <a href="http://hl7.org/fhir/R5/">FHIR 5.0.0</a>. Generated <span title="Thu, Jan 16, 2025 09:02+0000">2025-01-16</span>
          <br/>
          <span style="color: #FFFF77">
            <p style="color: white"><a name="l808">​</a>
       Links: <a href="toc.html">Table of Contents</a> |
       <a href="qa.html">QA Report</a> |
       <a href="https://github.com/CODEX-CELIDA/de.uni-greifswald.medizin.cll-guideline/issues/" target="_blank">Issues</a> |
       <a href="https://github.com/CODEX-CELIDA/de.uni-greifswald.medizin.cll-guideline/issues/new" target="_blank">Submit an issue</a> |
       <a href="http://hl7.org/fhir/R5//history.html" target="_blank">Version History</a> |
       <a rel="license" href="http://hl7.org/fhir/R5/license.html"><img src="assets/images/cc-by.svg" alt="CC-BY" style="border-style: none;" height="17"/></a> |
</p>

<script src="assets/js/imageMapResizer.min.js" type="text/javascript"></script>
<script type="text/javascript">
       imageMapResize();
</script>

          </span>
        </p>
      </div>    <!-- /inner-wrapper -->
    </div>    <!-- /container -->
  </div>    <!-- /segment-footer -->

  <div id="segment-post-footer" class="segment hidden">    <!-- segment-post-footer -->
    <div class="container">    <!-- container -->
    </div>    <!-- /container -->
  </div>    <!-- /segment-post-footer -->

    <!-- JS and analytics only. -->
    <!-- Bootstrap core JavaScript -->

    <!-- Placed at the end of the document so the pages load faster -->
  <script src="assets/js/bootstrap.min.js" type="text/javascript"> </script>
  <script src="assets/js/respond.min.js" type="text/javascript"> </script>
  <script src="assets/js/anchor.min.js" type="text/javascript"> </script>
  <script>anchors.options.visible = 'hover'
anchors.add()</script>

    <!-- feedback form - Google forms -->
  <!-- v0.1, 2021-01-09 -->



  <!-- / feedback form -->

    <!-- Analytics Below
  ================================================== -->
  </body>
</html>